# A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

> **NCT01220947** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 421 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Copegus
- **DRUG:** Danoprevir
- **DRUG:** Danoprevir
- **DRUG:** Danoprevir
- **DRUG:** Pegasys
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT01220947
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220947, "A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01220947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*